<?xml version="1.0" encoding="UTF-8"?>
<p>While price was once the limiting factor blocking access to DAAs, with increasing availability of affordable generics this is no longer the case in many countries. Though falling prices have increased treatment uptake, the major challenge in tackling the HCV epidemics is not only access to treatment or affordability, but a lack of knowledge: 90% of people living with viral hepatitis are unaware of their status.</p>
